scholarly journals A Case of Cutaneous Leishmaniasis Responding to Systemic Liposomal Amphotericin B Treatment

2020 ◽  
Vol 54 (4) ◽  
pp. 247-250
Author(s):  
Esra Çakmak Taşkın ◽  
Hatice Büşra Kütükçü ◽  
Hatice Kübra Konca ◽  
Gül Arga ◽  
Halil Özdemir ◽  
...  
Keyword(s):  
Side Effects ◽  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Alternative Treatment ◽  
Liposomal Amphotericin ◽  
Local Treatment ◽  
Treatment Modalities ◽  
Pentavalent Antimony ◽  
Insufficient Response ◽  
Cutaneous Form

Leishmania is a vector-induced endemic tropical disease caused by protozoans. The most common cutaneous, mucosal and visceral forms are the cutaneous form. The main drugs in treatment are pentavalent antimony compounds, but their side effects create limitation of use. Local antimony compounds are used primarily in the treatment of cutaneous leishmaniasis. In some cases, alternative treatment modalities are required due to insufficient response to local treatment. Systemic amphotericin B treatment is one of the alternative treatments. In a patient who developed cutaneous leishmania at 21 months and who did not respond with local meglumine antimoniate therapy, a total of 21 mg / kg dose of systemic amphotericin B was given intermittently and successful results were obtained.

scholarly journals A Case of Cutaneous Leishmaniasis Responding to Systemic Liposomal Amphotericin B Treatment

2020 ◽  
Vol 54 (4) ◽  
pp. 229-232
Author(s):  
Esra Çakmak Taşkın ◽  
Hatice Büşra Kütükçü ◽  
Hatice Kübra Konca ◽  
Gül Arga ◽  
Halil Özdemir ◽  
...  
Keyword(s):  
Side Effects ◽  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Alternative Treatment ◽  
Liposomal Amphotericin ◽  
Local Treatment ◽  
Treatment Modalities ◽  
Pentavalent Antimony ◽  
Insufficient Response ◽  
Cutaneous Form

Leishmania is a vector-induced endemic tropical disease caused by protozoans. The most common cutaneous, mucosal and visceral forms are the cutaneous form. The main drugs in treatment are pentavalent antimony compounds, but their side effects create limitation of use. Local antimony compounds are used primarily in the treatment of cutaneous leishmaniasis. In some cases, alternative treatment modalities are required due to insufficient response to local treatment. Systemic amphotericin B treatment is one of the alternative treatments. In a patient who developed cutaneous Leishmania at 21 months and who did not respond with local meglumine antimoniate therapy, a total of 21 mg/kg dose of systemic amphotericin B was given intermittently and successful results were obtained.

scholarly journals Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B

Pathogens ◽  
2021 ◽  
Vol 10 (10) ◽  
pp. 1253
Author(s):  
Maria Ubals ◽  
Pau Bosch-Nicolau ◽  
Adrián Sánchez-Montalvá ◽  
Fernando Salvador ◽  
Gloria Aparicio-Español ◽  
...  
Keyword(s):  
Adverse Events ◽  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Local Treatment ◽  
University Hospital ◽  
Liposomal Amphotericin B ◽  
First Year ◽  
Drug Safety Surveillance ◽  
Alternative Treatment Option

Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. Methods: We performed a retrospective study in Vall d’Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. Results: The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. Conclusions: L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.

scholarly journals Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Pouran Layegh ◽  
Omid Rajabi ◽  
Mahmoud Reza Jafari ◽  
Parisa Emamgholi Tabar Malekshah ◽  
Toktam Moghiman ◽  
...  
Keyword(s):  
Side Effects ◽  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
Attractive Alternative ◽  
Intention To Treat ◽  
Treatment Side Effects ◽  
Significant Difference ◽  
Clinical Responses

Background. Topical treatment of cutaneous leishmaniasis is an attractive alternative avoiding toxicities of parenteral therapy while being administered through a simple painless route. Recently liposomal formulations of amphotericin B have been increasingly used in the treatment of several types of leishmaniasis.Aims. The efficacy of a topical liposomal amphotericin B formulation was compared with intralesional glucantime in the treatment of cutaneous leishmaniasis.Methods. From 110 patients, the randomly selected 50 received a topical liposomal formulation of amphotericin B into each lesion, 3–7 drops twice daily, according to the lesion's size and for 8 weeks. The other group of 60 patients received intralesional glucantime injection of 1-2 mL once a week for the same period. The clinical responses and side effects of both groups were evaluated weekly during the treatment course.Results. Per-protocol analysis showed no statistically significant difference between the two groups (, 95% confidence interval (0.632–4.101)). Moreover, after intention-to-treat analysis, the same results were seen (, 95% (0.560–2.530)). Serious post treatment side effects were not observed in either group.Conclusions. Topical liposomal amphotericin B has the same efficacy as intralesional glucantime in the treatment of cutaneous leishmaniasis.

Cutaneous leishmaniasis in a Japanese returnee from West Africa successfully treated with liposomal amphotericin B

2011 ◽  
Vol 38 (11) ◽  
pp. 1062-1065 ◽  
Author(s):  
Misaki ONO ◽  
Kenzo TAKAHASHI ◽  
Kiyohito TAIRA ◽  
Hirosi UEZATO ◽  
Saori TAKAMURA ◽  
...  
Keyword(s):  
West Africa ◽  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B

Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis

2005 ◽  
Vol 153 (1) ◽  
pp. 203-205 ◽  
Author(s):  
M. Brown ◽  
M. Noursadeghi ◽  
J. Boyle ◽  
R.N. Davidson
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
Leishmania Braziliensis

scholarly journals Rhinophyma-Like Cutaneous Leishmaniasis due to Leishmania aethiopica Treated Successfully with Liposomal Amphotericin B

2019 ◽  
Vol 100 (2) ◽  
pp. 231-232 ◽  
Author(s):  
Michael Constantin Kirchberger ◽  
Stefan Schliep ◽  
Christian Bogdan
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
Leishmania Aethiopica

scholarly journals Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B

2018 ◽  
Vol 62 (10) ◽  
Author(s):  
Gert-Jan Wijnant ◽  
Katrien Van Bocxlaer ◽  
Amanda Fortes Francisco ◽  
Vanessa Yardley ◽  
Andy Harris ◽  
...  
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Skin Inflammation ◽  
Skin Lesions ◽  
Disease Stage ◽  
Liposomal Amphotericin B ◽  
Local Skin ◽  
Content Type ◽  
Tissue Inflammation

ABSTRACTDisfiguring skin lesions caused by several species of theLeishmaniaparasite characterize cutaneous leishmaniasis (CL). Successful treatment of CL with intravenous (i.v.) liposomal amphotericin B (LAmB) relies on the presence of adequate antibiotic concentrations at the dermal site of infection within the inflamed skin. Here, we have investigated the impact of the local skin inflammation on the pharmacokinetics (PK) and efficacy of LAmB in two murine models of localized CL (Leishmania majorandLeishmania mexicana) at three different stages of disease (papule, initial nodule, and established nodule). Twenty-four hours after the administration of one 25 mg/kg of body weight LAmB (i.v.) dose to infected BALB/c mice (n= 5), drug accumulation in the skin was found to be dependent on the causative parasite species (L. major>L. mexicana) and the disease stage (papule > initial nodule > established nodule > healthy skin). Elevated tissue drug levels were associated with increased vascular permeability (Evans blue assay) and macrophage infiltration (histomorphometry) in the infected skin, two pathophysiological parameters linked to tissue inflammation. After identical treatment of CL in the two models with 5 × 25 mg/kg LAmB (i.v.), intralesional drug concentrations and reductions in lesion size and parasite load (quantitative PCR [qPCR]) were all ≥2-fold higher forL. majorthan forL. mexicana. In conclusion, drug penetration of LAmB into CL skin lesions could depend on the disease stage and the causativeLeishmaniaspecies due to the influence of local tissue inflammation.

Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B

2005 ◽  
Vol 51 (5) ◽  
pp. e261-e264 ◽  
Author(s):  
A. Paradisi ◽  
R. Capizzi ◽  
A. Zampetti ◽  
I. Proietti ◽  
C. De Simone ◽  
...  
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Immunocompetent Patient ◽  
Liposomal Amphotericin B
Sign in / Sign up

Export Citation Format

Share Document